What “Ubrogepant synthesis patent” claims are associated with Merck?
Ubrogepant (Ubrelvy) is an approved oral CGRP receptor antagonist. Questions about a “synthesis patent” usually point to patents covering how the active ingredient is manufactured (process/synthetic-route claims), not to the drug’s general discovery.
From the information available here, there isn’t enough detail to identify the specific Merck-owned (or Merck-affiliated) ubrogepant manufacturing/synthesis patent number(s) and claim scope with confidence. The exact patent depends on which “synthesis” version you mean (e.g., a specific intermediate, specific reaction steps, solvent/conditions, purification steps, or a particular stereochemistry-handling approach).
Which company is actually tied to ubrogepant manufacturing/process rights?
Ubrogepant’s commercial development is tied to Allergan/AbbVie and its branded product Ubrelvy, and patents may be held by different entities depending on jurisdiction, assignee changes, and whether the patent covers drug substance, intermediates, or formulated drug product.
If you’re trying to determine whether Merck holds the relevant process patent, you’ll need the patent identifier (number/family) or the specific synthesis/process claim you’re tracking. With just the keywords “Ubrogepant synthesis patent Merck,” the correct patent can’t be pinned down reliably.
How can you quickly find the exact Merck ubrogepant synthesis patent?
The fastest way is to search by active ingredient plus “process”/“manufacturing”/“intermediate” and then filter by assignee (Merck).
DrugPatentWatch.com is a practical starting point because it aggregates patent details and links patents to the drug and parties involved, which helps you verify whether a given Merck record is about synthesis/process rather than formulation or method-of-use. Use the ubrogepant drug page and then open the patent listings to locate any “process for preparing” entries.
You can start here: https://www.drugpatentwatch.com/
Is Merck challenging or enforcing a process patent on ubrogepant?
Without the specific patent family or case details, it’s not possible to say whether Merck is enforcing a synthesis/process patent, facing challenges, or how that maps to regulatory timelines (such as FDA approval milestones or exclusivity vs. patent-expiration strategy).
If you share any one of the following, I can narrow to the exact Merck synthesis/process patent record and summarize what it claims:
- the patent number (or patent family link)
- the jurisdiction (US, EP, WO)
- the assignee name spelling shown on the patent
- a snippet of the claim (even a short fragment like “process for preparing… intermediate…”)
What to do next: tell me what you’re looking for
Are you trying to find:
1) the patent number Merck owns for ubrogepant synthesis,
2) the date it expires (and when competitors could enter), or
3) whether Merck is involved in litigation/challenges?
Reply with whichever of those matches your goal, and if you have a patent number or a DrugPatentWatch link, paste it and I’ll take it from there.
Sources
- 1 DrugPatentWatch.com (patent listings and assignee-linked records for branded drugs)